Cargando…
An exploratory, randomised, placebo-controlled, 14 day trial of the soluble guanylate cyclase stimulator praliciguat in participants with type 2 diabetes and hypertension
AIMS/HYPOTHESIS: Praliciguat (IW-1973), a soluble guanylate cyclase stimulator, amplifies nitric oxide signalling. This exploratory trial investigated the safety, tolerability, pharmacokinetic profile and pharmacodynamic effects of praliciguat in individuals with type 2 diabetes and hypertension. ME...
Autores principales: | Hanrahan, John P., Seferovic, Jelena P., Wakefield, James D., Wilson, Phebe J., Chickering, Jennifer G., Jung, Joon, Carlson, Kenneth E., Zimmer, Daniel P., Frelinger, Andrew L., Michelson, Alan D., Morrow, Linda, Hall, Michael, Currie, Mark G., Milne, G. Todd, Profy, Albert T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7054374/ https://www.ncbi.nlm.nih.gov/pubmed/31858186 http://dx.doi.org/10.1007/s00125-019-05062-x |
Ejemplares similares
-
Pharmacokinetics, mass balance, tissue distribution, metabolism, and excretion of praliciguat, a clinical‐stage soluble guanylate cyclase stimulator in rats
por: Banijamali, Ali R., et al.
Publicado: (2020) -
SUN-662 Praliciguat, a Clinical-Stage Soluble Guanylate Cyclase Stimulator, Improves Lipid Handling and Insulin Sensitivity in Diet-Induced Obese Mice
por: Schwartzkopf, Chad D, et al.
Publicado: (2020) -
Beneficial Metabolic Effects of Praliciguat, a Soluble Guanylate Cyclase Stimulator, in a Mouse Diet-Induced Obesity Model
por: Schwartzkopf, Chad D., et al.
Publicado: (2022) -
Guanylate cyclase-C/cGMP: an emerging pathway in the regulation of visceral pain
por: Hannig, Gerhard, et al.
Publicado: (2014) -
Structural studies of soluble guanylate cyclase
por: Macdonald, Jane, et al.
Publicado: (2009)